Once-daily Nadroparin Versus Twice-daily Nadroparin in the Treatment of Patients with Acute Coronary Syndromes: The SAFRAX Study

摘要

We performed a randomised, open-labelled, pilot study to determine whether once-daily (od) nadroparin at double concentration could be as safe and effective as twice-daily (bid) nadroparin at standard concentration for the treatment of non-ST elevation acute coronary syndromes. A total of 710 patients subcutaneously received, either od nadroparin (19,000 anti-Xa IU/mL), or bid nadroparin (9,500 anti-Xa IU/mL) according to body weight for three days. Major haemorrhages occurred in six (1.6%) patients in the od group and three (0.9%) patients in the bid group (p=0.51). The respective incidences of the composite efficacy endpoint in the od and bid groups were 16.9% (62/366) and 17.4% (60/344) (p=0.86). Thus, od nadroparin is as safe and effective as bid nadroparin in the treatment of patients with acute coronary syndromes.